Tetra Therapeutics Reports Fragile X Treatment Improved Cognitive Function & Behavior In Phase 2 Clinical Trial

Tetra Therapeutics, a wholly owned subsidiary of Shionogi & Co. Ltd., announced positive topline results from its Phase 2 exploratory study in adults diagnosed with Fragile X Syndrome (FXS). The study evaluated its lead candidate, BPN14770. In this single-center, randomized, placebo-controlled, two-way crossover study, BPN14770 demonstrated excellent safety as well as benefits on cognitive function and behavior in 30 adults with FXS.

BPN14770 is a novel therapeutic agent that selectively inhibits phosphodiesterase‐4D (PDE4D). In preclinical studies, BPN14770 promoted the maturation of connections between neurons, which is impaired in people with FXS, the most common genetic form . . .